Supplement: The Atypical Atypical?

The Atypical Atypical? By Jonathan Scheff A new class of antipsychotics aims at NMDA receptors ARTICLE EXTRAS The Treatments A Troubled History First-Generation Antipsychotic Drugs The next generation? The Lessons of CATIE Second-Generation Antipsychotic Drugs Beyond Drugs Nonmedication Therapies Until the 1980s, researchers didn't consider the excitatory amino acid N-methyl-D-aspartate (NMDA) to be a receptor in mammalian brains. That began to c

Jonathan Scheff
Dec 1, 2007
The Atypical Atypical?
By Jonathan Scheff
A new class of antipsychotics aims at NMDA receptors

Until the 1980s, researchers didn't consider the excitatory amino acid N-methyl-D-aspartate (NMDA) to be a receptor in mammalian brains. That began to change in 1982, when Joerg Lehmann and Bernard Scatton studied the interaction between excitatory amino acids and striatal cholinergic neurons in vitro (Brain Res, 252:77-89, 1982). They suggested that excitatory amino acids such as glutamate act at NMDA receptors on the dendrites of striatal cholinergic interneurons.

Over the years, this line of research eventually demonstrated that in healthy human subjects, NMDA antagonists could cause the negative symptoms and cognitive impairments observed in schizophrenia (Cell Molec Neurobiol, 26:365-84, 2006). That led to the idea that NMDA...